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Caprazamycins are antimycobacterials produced by Streptomyces sp. MK730-62F2. Previously, cosmid
cpzLK09 was shown to direct the biosynthesis of caprazamycin aglycones, but not of intact caprazamycins.
Sequence analysis of cpzLK09 identified 23 genes involved in the formation of the caprazamycin aglycones and
the transfer and methylation of the sugar moiety, together with genes for resistance, transport, and regulation.
In this study, coexpression of cpzLK09 in Streptomyces coelicolor M512 with pRHAM, containing all the
required genes for dTDP–L-rhamnose biosynthesis, led to the production of intact caprazamycins. In vitro
studies showed that Cpz31 is responsible for the attachment of the L-rhamnose to the caprazamycin aglycones,
generating a rare acylated deoxyhexose. An L-rhamnose gene cluster was identified elsewhere on the Strepto-
myces sp. MK730-62F2 genome, and its involvement in caprazamycin formation was demonstrated by inser-
tional inactivation of cpzDIII. The L-rhamnose subcluster was assembled with cpzLK09 using Red/ET-mediated
recombination. Heterologous expression of the resulting cosmid, cpzEW07, led to the production of capraza-
mycins, demonstrating that both sets of genes are required for caprazamycin biosynthesis. Knockouts of cpzDI
and cpzDV in the L-rhamnose subcluster confirmed that four genes, cpzDII, cpzDIII, cpzDIV, and cpzDVI, are
sufficient for the biosynthesis of the deoxysugar moiety. The presented recombineering strategy may provide a
useful tool for the assembly of biosynthetic building blocks for heterologous production of microbial
compounds.
Caprazamycins are potent antimycobacterials isolated from
Streptomyces sp. MK730F-62F2 (23). In a pulmonary tubercu-
losis mouse model, they showed a therapeutic effect but no
significant toxicity (24). The caprazamycins are assigned to the
translocase I inhibitors (27) due to their structural similarity to
the liposidomycins (34, 43), which have been studied in more
detail. Translocase I catalyzes the first step in the membrane-
linked reaction cycle of bacterial cell wall formation (52): the
transfer of phospho–N-acetylmuramic acid–L-Ala–-D-Glu–m-
diaminopimelic acid–D-Ala–D-Ala from UMP to the lipid car-
rier undecaprenyl phosphate. Structurally unique in nature,
the caprazamycins and liposidomycins share a 5--O-amino-
ribosyl-glycyluridine and a rare N-methylated diazepanone as
their characteristic feature (Fig. 1) (25, 53). Attached at the 3
position are -hydroxylated fatty acid groups of different chain
lengths, carrying a 3-methylglutarate. While the liposidomycins
are sulfated, the caprazamycins lack this group. Instead, they
are glycosylated with a 2,3,4-O-methyl-L-rhamnose and there-
fore belong to the large number of bioactive compounds con-
taining 6-deoxyhexoses. Usually, these moieties contribute sig-
nificantly to the compounds’ properties, influencing, e.g.,
molecule-target interactions, cell import and export, pharma-
cokinetics, and solubility (56). The biosynthesis of deoxysugars
has been studied in detail and generally starts from NDP-
activated hexoses via 4-keto-6-deoxy intermediates (36). The
formation of L-rhamnose involves four enzymes, a dTDP–D-
glucose synthase, a dTDP–D-glucose 4,6-dehydratase, a dTDP–
3,5-deoxyglucose epimerase, and a 4-ketoreductase. Recent
advances in combinatorial biosynthesis have led to a variety of
novel natural products with an engineered glycosylation pat-
tern and altered bioactivity (37, 44). The key step in this ap-
proach is the attachment of different deoxysugars to the agly-
cones, which demands substrate-flexible glycosyltransferases.
We recently reported cloning and heterologous expression
of cosmid cpzLK09 containing the first identified gene cluster
of a translocase I inhibitor, the caprazamycins. However, genes
for the formation of the dTDP–L-rhamnose could not be iden-
tified on this cosmid (Fig. 1) and therefore only caprazamycin
aglycones were produced by the heterologous host, Streptomy-
ces coelicolor M512/cpzLK09 (31). The absence of genes for
the formation of the L-rhamnose moiety within the corre-
sponding biosynthetic gene cluster has previously been re-
ported for aranciamycin (38), steffimycin (16), spinosyn (55),
and elloramycin (9). Since potential genes for O methylation
(cpz28 to cpz30) and a glycosyltransferase (cpz31) are encoded
in the caprazamycin gene cluster, we speculated that only four
genes are missing for successful heterologous production of
intact caprazamycins.
Here we report the identification of the genes required for
the biosynthesis of the caprazamycin deoxysugar moiety else-
where on the genome of Streptomyces sp. MK730-62F2. A new
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strategy was developed, based on Red/ET-mediated recombi-
nation, to assemble the identified subcluster into cosmid
cpzLK09. Expression of the assembled cluster readily resulted
in the production of intact caprazamycins in the heterologous
producer strain. Moreover, in vitro studies demonstrated that
Cpz31 is the glycosyltransferase in caprazamycin biosynthesis.
MATERIALS AND METHODS
Bacterial strains and general methods. Chemicals and microbiological and
molecular biological agents were purchased from standard commercial sources.
Streptomyces sp. MK730-62F2 and S. coelicolor M512 (SCP1 SCP2, actIIorf4
redD) and their respective derivatives were maintained and grown on either MS
agar (2% soy flour, 2% mannitol, 2% agar [components purchased from Carl
Roth, Karlsruhe, Germany]) or trypic soy broth (TSB) medium (Becton Dick-
inson, Heidelberg, Germany). Escherichia coli strains were cultivated in LB
medium (components purchased from Carl Roth, Karlsruhe, Germany) supple-
mented with appropriate antibiotics. DNA isolation and manipulations were
carried out according to standard methods for E. coli (51) and Streptomyces (33).
Production, extraction, and detection of caprazamycin derivatives. Fifty mil-
liliters of TSB medium was inoculated with a spore suspension of Streptomyces
sp. MK730-62F2, S. coelicolor M512, or a derivative thereof. The cultures were
incubated for 2 days at 30°C and 200 rpm. For the production of caprazamycins,
1 ml of the precultures was inoculated into 100 ml of a medium containing 1%
soytone, 1% soluble starch, and 2% D-maltose adjusted to pH 6.7 (components
purchased from Becton Dickinson, Heidelberg, Germany). The cultures were
incubated for 7 days at 30°C and 200 rpm. Partial purification of caprazamycins
was achieved by extraction of the culture supernatant (adjusted to pH 4) with an
equal volume of n-butanol. The organic phase was evaporated, and extracts were
resolved in 500 l methanol. Liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis was performed on a Surveyor high-performance LC
(HPLC) system equipped with a Reprosil-Pur Basic C18 column (5 m; 250 by 2
mm; Maisch, Ammerbuch, Germany) coupled to a Thermo Finnigan TSQ Quan-
tum triple-quadrupole mass spectrometer (heated capillary temperature, 320°C;
sheath gas, nitrogen; collision gas, argon). Analysis of extracts from the coex-
pression of pRHAM experiments was performed with a linear gradient of 2% to
40% acetonitrile in aqueous formic acid (0.1%) over 5 min followed by a linear
gradient of 40% to 100% acetonitrile in aqueous formic acid (0.1%) over 20 min.
Otherwise, a linear gradient of 2% to 40% acetonitrile in aqueous formic acid
(0.1%) over 4 min was used followed by a linear gradient of 40% to 100%
acetonitrile in aqueous formic acid (0.1%) over 31 min. The flow rate was 0.2
liter min1, and detection was at 262 nm. Positive electrospray ionization [()-
ESI] was performed with an electrospray voltage of 3.8 kV, and collision-induced
dissociation (CID) spectra were recorded with a collision energy of 35 eV.
Coexpression of plasmid pRHAM. Plasmid pRHAM (49), containing all re-
quired genes for the biosynthesis of dTDP–L-rhamnose oleL, oleS, oleE, and oleU
from Streptomyces antibioticus ATCC 1891, was introduced into the nonmeth-
ylating strain E. coli ET12567 (40) and reisolated. The isolated plasmid DNA was
used for polyethylene glycol (PEG)-mediated protoplast transformation as de-
scribed by Kieser et al. (33) with either Streptomyces sp. MK730-62F2 cpzDIII
for complementation of the cpzDIII knockout or with S. coelicolor/cpzLK09 for
the production of intact caprazamycins. For the preparation of protoplasts, the
corresponding Streptomyces strain was cultivated in 100 ml S-YEME broth (34%
sucrose, 1% glucose, 0.5% peptone, 0.3% yeast extract, 0.3% malt extract, 5 mM
MgCl2; components purchased from Carl Roth, Karlsruhe, Germany) for 48 h at
30°C. Cells were harvested and washed with an aqueous solution of 10.3%
sucrose. The degradation of the cell wall was performed at 30°C in P buffer
[10.3% sucrose, 0.025% K2SO4, 0.202% MgCl2  6H2O, 0.005% KH2PO4,
0.368% CaCl2  2H2O, and 0.573% N-tris(hydroxymethyl)methyl-2-aminoeth-
anesulfonic acid] supplemented with 4 mg/ml lysozyme (Serva, Heidelberg, Ger-
many) and monitored by microscopy. Subsequently, PEG-mediated protoplast
transformation was performed. Thiostrepton resistance mutants were selected
and termed either Streptomyces sp. MK730-62F2/cpzDIII/pRHAM-(1-3) or S.
coelicolor/cpzLK09/pRHAM-(1-3).
Overexpression and purification of Cpz31. cpz31 was amplified from cosmid
DNA using the primers cpzGTEco_fw, GAATTCATGCGCGTGCTCTTC
ACG, and cpzGTHind_rv, AAGCTTCTAGGCCCTCCTCGCCAG (restriction
sites for EcoRI and HindIII are underlined). A 1.2-kb PCR product was cloned
into the pGEM-T cloning vector (Promega, Mannheim, Germany). The resulting
plasmid, pLK01, was verified by sequencing. cpz31 was subsequently cloned into
the expression vector pHis8 (29), taking advantage of the EcoRI and HindIII
restriction sites, and confirmed by sequencing. The resulting plasmid was named
pLK02.
E. coli Rosetta2 (DE3)pLys (Novagen, Darmstadt, Germany) cells containing
plasmid pLK02 were cultivated in 1 liter of TB broth (1.2% tryptone, 2.4% yeast
extract, 0.4% glycerol, 0.23% KH2PO4, 1.25% K2HPO4) supplemented with 50
g ml1 kanamycin and 50 g ml1 chloramphenicol at 37°C. At an optical
density at 600 nm of 0.7, the temperature was adjusted to 20°C, and isopropyl
thiogalactoside (IPTG) was added to a 0.5 mM final concentration. After an
additional 10-h cultivation at 20°C, the culture was harvested and 10 ml of buffer
A (50 mM Tris-HCl [pH 8], 1 M NaCl, 10% glycerol, 20 mM imidazole, 10 mM
-mercaptoethanol) supplemented with 0.5 mg ml1 lysozyme and 0.5 mM
phenylmethylsulfonyl fluoride was added to the pellet (12 g). Cells were dis-
FIG. 1. Structure of caprazamycins and organization of the caprazamycin gene cluster (cpz9 to cpz31) lacking the genes for deoxysugar
formation. Assignments of genes to different steps in the biosynthesis are indicated.
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rupted by sonication (Branson, Danbury, CT) at 4°C. The lysate was centrifuged
(55,000 	 g, 45 min), and the supernatant was applied to an affinity chromatog-
raphy column with 4 ml of Ni-nitrilotriacetic acid (NTA)–agarose resin (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. His8-Cpz31 was
eluted from the column with 250 mM imidazole in buffer A. Buffer exchange was
carried out with PD10 columns (Amersham Biosciences, Freiburg, Germany)
and buffer A without -mercaptoethanol and imidazole. The low solubility of
His8-Cpz31 resulted in a yield of 0.46 mg of partially purified protein per liter of
culture. The protein was stored at 80°C in aliquots of 50 l.
Assay for glycosyltransferase activity. Partially purified caprazamycin agly-
cones were obtained from a culture extract of S. coelicolor M512/cpzLK09. Five
microliters of caprazamycin aglycones in methanolic solution was applied to a
reaction tube, air dried, and dissolved in a 50-l reaction mixture containing 50
mM Tris-HCl, pH 7.5, 5 mM MgCl2, 5 mM dTDP–L-rhamnose, and 9 M
protein. The assay was performed at 30°C for 2 h and stopped by the addition of
150 l methanol. The activity of His8-Cpz31 was measured by LC-ESI-MS.
Screening of the cosmid library. The construction of the genomic cosmid
library of Streptomyces sp. MK730-62F2 has been described previously (31). A
0.5-kb fragment of cpzDIII was amplified from genomic DNA by using a degen-
erated primer as described by Decker et al. (8). Perfect matching primers
GDHspf_fw, CGTAGTTGTTGGAGCAGCGCG, and GDHspf_rv, GGTTCA
TCGGCTCCCGCTACG, amplifying a 0.5-kb fragment of cpzDIII, were applied
in a PCR screening of the cosmid library.
DNA sequencing and computer-assisted sequence analysis. Double-stranded
sequencing of the entire cosmid clone 4H11 (39,442-bp insert) was performed by
GenoTech (Baejeon, South Korea) by using a shotgun library with DNA frag-
ments of approximately 0.5 to 1.0 kb in length. The DNASIS software package
(Hitachi Software Engineering, Tokyo, Japan) and Artemis (Wellcome Trust
Genome Campus, Cambridge, United Kingdom) were used for sequence analysis
and annotation. Database comparisons were carried out in the GenBank data-
base by using the BLAST program (1). Alignment and comparison of sequences
were performed using the ClustalX algorithm (28) and GeneDoc alignment
editor (http://www.psc.edu/biomed/genedoc).
Inactivation of cpzDIII in Streptomyces sp. MK730-62F2. An apramycin resis-
tance cassette [aac(3)IV] was amplified from plasmid pIJ773 (18) using the
primer pair gdhKO_fw, GTGCTGGACAAGCTCACCTACGCCGGCACCCTC
GACGACATTCCGGGGATCCGTCGACC, and gdhKO_rv, GAGCTGGCAC
GGGCCGTAGTTGTTGGAGCAGCGCGTGACTGTAGGCTGGAGCTGC
TTC. Italic letters represent 39-nucleotide (nt) homologous extensions for Red/
ET-mediated recombination. The gene was replaced in E. coli BW25113/pIJ790/
4H11 by using Red/ET-mediated recombination (18), and the resulting cosmid,
cpzLK01, was confirmed by restriction analysis. cpzLK01 was transferred into the
nonmethylating strain E. coli ET12567/pUZ8002 (46) and introduced into Strep-
tomyces sp. MK730-62F2 by conjugation. Exconjugants, resistant to apramycin,
were isolated and tested for the loss of their kanamycin resistance, indicating a
successful double crossover. The mutants were further analyzed by PCR with
chromosomal DNA as the template. Mutant strains were designated Streptomy-
ces sp. MK730-62F2cpzDIII-(1-3). Complementation of the mutants was per-
formed by coexpression of plasmid pRHAM as described above.
Assembly of the caprazamycin biosynthetic gene cluster and the L-rhamnose
subcluster. An apramycin resistance cassette [aac(3)IV] was amplified by PCR
from plasmid pIJ774 (19) with primers 4H11_774_fw, GCCCGAGCACCCGCA
GCCGGTTCGCCCGCGAGCCCAGCAGCTAGCTTATGAGCAGCCAATC
GAC, including a NheI restriction site (bold), and 4H11_774_rv, CAGAGGGT
GCGCTCGGAAGACGGGCGCGGAAGCCGCCCGACTAGTATTCCGGGG
ATCCGTCGACC, including a SpeI restriction site (bold). Italic letters
represent 39-nt homologous extensions to an internal region of orf1 and to a
region downstream of orf9, respectively. The resulting 1,310-bp PCR product
contained the aac(3)IV gene and a single loxP site. The PCR product was
inserted into cosmid 4H11 by Red/ET-mediated recombination (18), thereby
replacing a 13,531-bp region (orf1 to orf9) upstream of cpzDI, resulting in the
apramycin- and kanamycin-resistant cosmid cpzEW01. A hygromycin resistance
cassette (hyg) was amplified from pIJ10700 by PCR with primers 4H11_
10700_fw, TGACGGGCGGGCGGGGCTCGCAGCCCCTAGGCTGAGGAGA
TTTAAATTGTAGGCTGGAGCTGCTTC, including a SwaI restriction site
(bold), and 4H11_10700_rv, GGGGGCCGTCGCCGAAGTGCGGGCCGCCG
GGCGGCACGGGTTTAAACATTCCGGGGATCCGTCGACC, including a
PmeI restriction site (bold). Italic letters represent 39-nt homologous extensions
to sequences upstream of orf10 and to an internal region of orf25, respectively.
The resulting 1,678-bp PCR product contained the hygromycin resistance gene
hyg, an origin of transfer, oriT, and was flanked by two FLP recombinase recog-
nition sites (FRT). The PCR product was inserted into cosmid cpzEW01 by
Red/ET-mediated recombination, thereby replacing a 16,144-bp region (orf10 to
orf25) upstream of cpzDVII and resulting in the hygromycin-, apramycin-, and
kanamycin-resistant cosmid cpzEW02. Restriction of cpzEW02 with NheI and
PmeI generated the 9,950-bp L-rhamnose subcluster fragment (cpzDI to
cpzDVII) flanked by the apramycin and the hygromycin resistance cassettes.
Cosmid cpzLK09, which already contained the 
C31 integration cassette from
pIJ787 (10), was prepared as the L-rhamnose subcluster acceptor cosmid. An apra-
mycin resistance cassette [aac(3)IV] was amplified from pIJ774 (18) by PCR with
primers 31C2_774_fw2, TGCCGTACCCGCGGTCACCGGTTCCGCCTCGGCG
GGTGCACTAGTTGTAGGCTGGAGCTGCTTC, including a SpeI restriction site
(bold), and 31C2_774_rv, CGTGCTGGTGCTCGCCAACCACCCCATGCGGCTG
GGCATGCTAGCAAATGCCGGCCTTTGAATGG, including a NheI restriction
site (bold). Italic letters represent 39-nt homologous extensions to sequences down-
stream of cpz31 and to an internal region of cpz33, respectively. The resulting
1,079-bp PCR product contained the aac(3)IV gene and a single loxP site. The PCR
product was inserted into cosmid cpzLK09 by Red/ET-mediated recombination,
thereby replacing a 1,000-bp region downstream of cpz31 and resulting in the apra-
mycin- and kanamycin-resistant cosmid cpzEW03. A spectinomycin/streptomycin
resistance cassette (aadA) was amplified from pIJ778 (18) by PCR with primers
31C2_778_fw, TCGTCAGATGCAGATGGACGTCGTGCCCGGCCGCGTTCTA
TTTAAATTTATTTGCCGACTACCTTGG, including a SwaI restriction site
(bold), and 31C2_778_rv, CCGCGGTGGCGCACCACGACGAACTGGTGCCGC
GGGCCGGTTTAAACATTCCGGGGATCCGTCGACC, including a PmeI re-
striction site (bold). Italic letters represent 39-nt homologous extensions to an in-
ternal sequence of cpz34 and to a region 351 bp upstream of cpz34, respectively. The
resulting 1,406-bp PCR product contained the aadA gene, an oriT, and a single FRT
site. The PCR product was inserted into cosmid cpzEW03, thereby replacing the
613-bp region between aac(3)IV and the beginning of the SuperCos1 backbone and
resulting in the spectinomycin-streptomycin-, apramycin-, and kanamycin-resistant
cosmid cpzEW05.
For the generation of cpzEW07, the cosmid containing the caprazamycin gene
cluster, and the L-rhamnose subcluster, Red/ET-mediated recombination was
used. A Red/ET-proficient E. coli strain harboring cpzEW05 was transformed
with the 9,950-bp NheI/PmeI fragment from cpzEW02. Homologous recombi-
nation took place between a 924-bp region, represented by the apramycin resis-
tance gene aac(3)IV, and a 523-bp region of identical sequence between the
hygromycin and the spectinomycin-streptomycin resistance cassettes. Positive
selection with hygromycin was possible for this recombination event due to the
exchange of the resistance gene aadA with hyg. Note that after Red/ET-mediated
recombination, the apramycin resistance cassette is now flanked by loxP sites and
the hygromycin resistance cassette by FRT sites, allowing removal of the resis-
tance cassettes by the use of Cre recombinase or FLP recombinase, respectively.
The isolated cosmid DNA of cpzEW07 was verified by restriction analysis.
cpzEW07 was introduced into S. coelicolor M512 by triparental intergeneric
conjugation with the help of E. coli ET12567/pUB307 (14). Apramycin-, hygro-
mycin-, and kanamycin-resistant clones were selected and termed S. coelicolor
M512/cpzEW07-(1-3).
Inactivation of cpzDI and cpzDV in S. coelicolor M512/cpzEW07. The apramy-
cin resistance cassette in cosmid cpzEW07 was eliminated by SpeI restriction and
religation as described elsewhere (17). The resulting cosmid cpzEW08 was ver-
ified by restriction analysis. An apramycin resistance cassette [aac(3)IV] was
amplified from plasmid pIJ774 (18) by PCR with primers containing an AflII site
(bold), KOcpzDI_fw, GTGGAAGCAGAAGGAAGATGATGAGTCGTGGAGT
CCATGCTTAAGATTCCGGGGATCCGTCGACC, and KOcpzDI_rv, GCTCG
GATCGTCACCGCGCTGTCCACGAGGGAGGCGTCACTTAAGTGTAGGC
TGGAGCTGCTTC, for the inactivation of cpzDI, or KOcpzDV_fw, GCATCC
GCAAGGAAGGTCTTCCTCGTGAAACGCCATGAGCTTAAGATTCCGGG
GATCCGTCGACc, and KOcpzDV_rv, CGCCGGCCGCCCCCGGGCGGTG
GCCGGCGCCGTCGTTCACTTAAGTGTAGGCTGGAGCTGCttc, for the in-
activation of cpzDV. Italic letters represent 39-nt homologous extensions to
sequences up- and downstream of the target genes for Red/ET-mediated recom-
bination. Resulting cosmids cpzEW09 [cpzDI::aac(3)IV] and cpzEW11
[cpzDV::aac(3)IV] were confirmed by restriction analysis. Excision of the cas-
sette was performed by in vitro application of Cre recombinase (New England
Biolabs, Frankfurt am Main, Germany) according to the manufacturer’s instruc-
tions, taking advantage of the loxP recognition sites flanking the apramycin
resistance cassette. The obtained cosmids cpzEW10 (cpzDI) and cpzEW12
(cpzDV) were screened for apramycin sensitivity and verified by restriction
analysis. Cosmids cpzEW10 and cpzEW12 were transferred into E. coli ET12567
(40) and introduced into S. coelicolor M512 by triparental intergeneric conjuga-
tion with the help of E. coli ET12567/pUB307 (14). Kanamycin resistance ex-
conjugants were selected and designated S. coelicolor M512/cpzEW10-(1-3)
(cpzDI) and S. coelicolor M512/cpzEW12-(1-3) (cpzDV).
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Nucleotide sequence accession number. The nucleotide sequence of the gene
cluster for dTDP-L-rhamnose biosynthesis, cpzDI through cpzDVII, has been
deposited in GenBank under the accession number HM051054.
RESULTS
Coexpression of pRHAM in S. coelicolor containing the
caprazamycin gene cluster. Previously, we reported that het-
erologous expression of cosmid cpzLK09, containing the
caprazamycin gene cluster, resulted in the accumulation of
caprazamycin aglycones in S. coelicolor M512 (31). The pro-
duction of the nonglycosylated caprazamycin derivatives cor-
relates with the absence of putative genes for the deoxysugar
formation within the gene cluster. In order to investigate if all
other genes required for the biosynthesis of the intact capraza-
mycins are functionally expressed on cpzLK09, we introduced
plasmid pRHAM (49) into the heterologous host S. coelicolor
M512/cpzLK09. pRHAM contains all genes required for
dTDP–L-rhamnose biosynthesis from S. antibioticus: oleS, en-
coding a dTDP-glucose synthase, oleE, a dTDP-glucose 4,6-
dehydratase, oleL, a dTDP-deoxyglucose 3,5-epimerase, and
oleU, a 4-ketoreductase. Three individual clones termed S.
coelicolor M512/cpzLK09/pRHAM-(1-3) were selected by their
thiostrepton resistance and cultivated in production medium.
Analysis of the culture extracts by LC-ESI-MS revealed that in
comparison to S. coelicolor M512/cpzLK09, which only pro-
duced the caprazamycin aglycones (Fig. 2B; CPZ aglycones
E/F with a retention time [Rt] of 18.2 min, CPZ aglycones
C/D/G with Rt of 19.0 min, and CPZ aglycones A/B with Rt of
20.2 min), all mutant strains now accumulated additional me-
tabolites (Fig. 2C). These new compounds correspond to the
caprazamycins E/F (Rt, 20.0 min), caprazamycins C/D/G (Rt,
20.9 min), and caprazamycins A/B (Rt, 22.3 min), as found by
ESI-MS product ion scans (see Fig. S1 in the supplemental
material). MS/MS spectra from CID experiments (see Fig. S1)
matched exactly the characteristic fragmentation profiles of the
intact caprazamycins (31). This verified that the enzymes for
methylation and attachment of the L-rhamnose moiety have to
be encoded on the gene cluster. A set of genes, cpz28 to -31,
encoding three hypothetical sugar O-methyltransferases and a
putative rhamnosyltransferase, are the most likely candidates
for these reactions.
In vitro investigation of Cpz31 with dTDP–L-rhamnose as
substrate. Cpz31 shows high sequence homology to known
rhamnosyltransferases from other antibiotic gene clusters, e.g.,
ElmGT from S. olivaceus (38% identity, 50% similarity) (4).
pLK02 containing cpz31 was overexpressed in E. coli, and the
resulting protein was purified for in vitro studies. His8-Cpz31
consists of 420 amino acids with a calculated molecular mass of
44.7 kDa. Expression of a corresponding protein could be
observed after induction with IPTG (see Fig. S2 in the supple-
mental material). Solubility of the enzyme was low, and the
yield could not be improved using different culture tempera-
tures or IPTG concentrations for expression. However, His8-
Cpz31 was partially purified by Ni-NTA chromatography, re-
sulting in 0.85 mg of protein from a 1-liter culture (see Fig. S2).
A butanolic extract from an S. coelicolor M512/cpzLK09 cul-
ture containing caprazamycin aglycones was incubated with
His8-Cpz31 in the presence of dTDP–L-rhamnose. After 2 h,
caprazamycin aglycones could not be observed in the assay
mixture anymore, and instead three new peaks appeared in the
LC chromatograms (Fig. 3B; at Rts of 17.2 min, 18.2 min, and
19.7 min), indicating product formation. Precursor ions for the
rhamnosylated caprazamycins E/F with m/z 1,076.6 [MH],
C/D/G with m/z 1,090.6 [MH], and A/B with m/z 1,104.6
[MH] were readily detected by ESI-MS product ion scans
at Rts of 17.4 min, 18.5 min, and 19.9 min, respectively (Fig.
3C). The MS/MS spectrum obtained from the parent ion with
m/z 1,090.6 [MH] (Fig. 3D) was identical to the predicted
fragmentation of the rhamnosylated caprazamycins C/D/G
(Fig. 3A). Characteristic ions with m/z 1,091, m/z 960, and m/z
848 displayed the presence of the rhamnosyl moiety. Similar
spectra were produced by the parent ions with m/z 1,076.6
[MH] and m/z 1,104.6 [MH], representing the rhamno-
FIG. 2. HPLC chromatograms of n-butanolic extracts from S.
coelicolor M512 (A), S. coelicolor M512 containing the caprazamy-
cin gene cluster cpzLK09 (B) and S. coelicolor M512/cpzLK09 con-
taining pRHAM coexpressing the biosynthetic genes for dTDP–L-
rhamnose (C).
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sylated caprazamycins with different fatty acid chain lengths
(data not shown). These compounds were not detectable in
assay mixtures without Cpz31 or dTDP–L-rhamnose. There-
fore, we conclude that Cpz31 glycosylates the caprazamycin
aglycones by using dTDP–L-rhamnose as a substrate (Fig. 3A).
Identification of genes for biosynthesis of dTDP–L-rham-
nose. In bacteria, genes directing the biosynthesis of a certain
secondary metabolite are generally clustered together. How-
ever, cosmid 31C2, containing the caprazamycin gene cluster,
missed the genes for the formation of the L-rhamnose moiety
(31). Because these genes are required for caprazamycin bio-
synthesis, they have to be located elsewhere on the chromo-
some of the original producer strain Streptomyces sp. MK730-
62F2. Using degenerated primers for the amplification of
NDP-glucose 4,6-dehydratases (8), we obtained a 500-bp par-
tial sequence of cpzDIII from genomic DNA of the capraza-
mycin producer. This fragment was cloned and sequenced.
Annotation revealed high homology to dTDP-glucose 4,6-de-
hydratases on the protein level. Perfect matching primers were
constructed to screen a cosmid library of Streptomyces sp.
MK730-62F2 (31). Sequencing and annotation of a positive
cosmid, 4H11, revealed a stretch of 6.8 kb of DNA putatively
involved in the biosynthesis of dTDP–L-rhamnose (Fig. 4).
According to the gene function predictions (Table 1), cpzDII
encodes a putative dTDP-glucose synthase, cpzDIII encodes a
dTDP-glucose 4,6-dehydratase, cpzDIV encodes a 4-ketore-
ductase, and cpzDVI encodes a dTDP-deoxyglucose 3,5-epi-
merase. The identified gene cluster consists of two putative
operons (Fig. 4). cpzDII, cpzDIII, and cpzDIV are translation-
ally coupled to cpzDV, as indicated by overlap of the stop and
start codons. The deduced gene product of cpzDV shows ho-
mology to hypothetical proteins from various Streptomyces strains
which are annotated as methyltransferases. In the opposite direc-
tion, cpzDVI is translationally coupled with cpzDVII, which en-
codes a putative glycosyltransferase. Homologues of CpzDVII
have been assigned to bacterial cell wall biosynthesis. The puta-
tive gene cpzDI, 105 bp upstream of cpzDII, encodes a small
protein of 57 amino acids with several homologues from Strep-
tomyces genomes. Many of them, e.g., SvirD4_37404 from
Streptomyces viridochromogenes DSM40736 and SAMR0798
from Streptomyces ambofaciens ATCC 23877, are located next
FIG. 3. Glycosylation of caprazamycins by Cpz31. (A) Reaction scheme of Cpz31 with dTDP–L-rhamnose and caprazamycin D aglycone as
substrates. The suggested fragmentation of the reaction product 2c,3c,4c-desmethyl-caprazamycin D is depicted. (B) Overlay of HPLC chromato-
grams (262 nm) from activity assays with Cpz31 (black line) and without protein (dashed line). The observed shift in retention time by the complete
conversion of caprazamycin aglycones to the rhamnosylated product is indicated by bold arrows. (C) LC-ESI-MS product ion scans in positive
mode for desmethyl-caprazamycins E/F with m/z 1,076.6 [MH], for desmethyl-caprazamycins C/D/G with m/z 1,090.6 [MH], and for
desmethyl-caprazamycins A/B with m/z 1,104.6 [MH] in the activity assay with Cpz31. (D) Mass spectrometric fragmentation pattern in the CID
experiment for 2c,3c,4c-desmethyl-caprazamycin C/D/G.
FIG. 4. Organization of the L-rhamnose gene cluster cpzDI to
cpzDVII on cosmid 4H11. Black arrows indicate genes proposed to be
essential in dTDP-L-rhamnose biosynthesis. Gray arrows indicate
genes with unknown function. Squared brackets above the cluster
mark the gene deletions performed in this study. The minus sign
indicates that the deletion of the respective region led to an abolish-
ment of caprazamycin production. Plus signs indicate that caprazamy-
cin production was not influenced.
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to hypothetical NDP-glucose dehydratase genes. Since orf9, a
putative oxidoreductase gene, and orf10, a possible phospho-
diesterase gene, have no apparent role in deoxysugar metab-
olism, we proposed that the L-rhamnose biosynthetic gene clus-
ter spans from cpzDI to cpzDVII.
Inactivation of cpzDIII and complementation with pRHAM.
In order to confirm the involvement of the postulated L-rham-
nose biosynthetic gene cluster in caprazamycin biosynthesis,
the hypothetical dTDP-glucose 4,6-dehydratase gene cpzDIII
was inactivated. The resulting cosmid, cpzLK01, was intro-
duced into Streptomyces sp. MK730-62F2 by intergeneric con-
jugation. Four double-crossover mutants of Streptomyces sp.
MK730-62F2 cpzDIII were finally selected and confirmed by
PCR. After cultivation, extracts of the mutant strains were
applied to LC-ESI-MS analysis. In contrast to the wild-type
strain, production of intact caprazamycins was completely
abolished in the mutants (see Fig. S3 in the supplemental
material). However, caprazamycin aglycones could clearly be
detected, and extracts of the mutants still showed bioactivity in
an agar diffusion assay against Mycobacterium phlei (data not
shown). In order to validate that the disruption of cpzDIII is
responsible for the abolishment of caprazamycin production,
we complemented the cpzDIII mutant by introducing
pRHAM. After cultivation, LC-ESI-MS analysis showed that
caprazamycin production was restored (see Fig. S3). Analysis
of the cpzDIII mutant and the complementation confirmed
that the L-rhamnose biosynthetic gene cluster on cosmid 4H11
is required for the formation of the L-rhamnose moiety in
caprazamycin biosynthesis.
Assembly of the entire gene cluster for heterologous produc-
tion of intact caprazamycins. In order to prove that the iden-
tified genes, cpzDI to -VII, are sufficient for L-rhamnose bio-
synthesis, we assembled the subcluster to cosmid cpzLK09
containing the caprazamycin gene cluster (Fig. 5A). It was
shown previously that the genes cpz32 to cpz34 are not involved
in caprazamycin biosynthesis, based on inactivation experi-
ments (31). Therefore, an apramycin resistance cassette and a
spectinomycin-streptomycin resistance cassette were used to
replace cpz32 to cpz34 by Red/ET-mediated recombination,
generating cosmid cpzEW05. Within cosmid 4H11, containing
the L-rhamnose subcluster, a 14-kb stretch of DNA upstream
of cpzDI was replaced with an apramycin resistance cassette,
introducing a unique NheI restriction site. A 17-kb fragment
upstream of cpzDVII was replaced by a hygromycin resistance
cassette, introducing a unique PmeI restriction site. From the
generated cosmid cpzEW02, a 10-kb PmeI/NheI restriction
fragment, containing the cpzDI-DVII subcluster, was trans-
ferred into Red/ET-proficient E. coli cells harboring cpzEW05.
Homologous recombination of the restriction fragment with
cosmid cpzEW05 was possible between the apramycin resis-
tance gene aac(3)IV (924 bp) and 523-bp identical sequences
of the hygromycin and the spectinomycin-streptomycin resis-
tance cassettes. These sequences include an oriT and an FRT
site. Red/ET-mediated recombination would lead to an apra-
mycin-, hygromycin-, and kanamycin-resistant transformant
only if homologous recombination occurred within these re-
gions.
The resulting cosmid, cpzEW07, was introduced into S.
coelicolor M512 by intergeneric triparental conjugation. Posi-
tive clones were selected by their apramycin, hygromycin, and
kanamycin resistance and termed S. coelicolor M512/cpzEW07.
The mutant strain was cultivated, and extracts were analyzed
by LC-ESI-MS. Three new peaks appeared in the UV chro-
matograms at retention times of 20.7 min, 22.1 min, and 23.8
min (Fig. 5B). These peaks were missing in extracts of S.
coelicolor M512 and S. coelicolor M512/cpzLK09 (data not
shown). Corresponding mass peaks were detected by product
ion scanning for the caprazamycins E/F with m/z 1,118.8
[MH] (Rt 20.9 min), caprazamycins C/D/G with m/z 1,132.8
[MH] (Rt, 22.3 min), and the caprazamycins A/B with m/z
1,146.8 [MH] (Rt, 24.0 min) (Fig. 5B). MS/MS fragmenta-
tion patterns matched exactly the intact caprazamycins (data
not shown). The heterologous production of caprazamycins in
S. coelicolor M512 containing the assembled gene cluster
proves that the cpzDI to -VII subcluster is sufficient for the
biosynthesis of dTDP–L-rhamnose.
Deletion of nonessential genes in the L-rhamnose subclus-
ter. The production of intact caprazamycins by expression of
the assembled gene cluster now enabled us to investigate other
genes in caprazamycin biosynthesis in a heterologous back-
ground. However, to allow further gene deletion experiments,
the existing apramycin resistance cassette needed to be elimi-
nated from cosmid cpzEW07. This was achieved by a SpeI
digestion and religation procedure, generating cosmid
TABLE 1. Deduced functions of genes within the L-rhamnose subcluster
Genea No. ofamino acids Protein homologue (accession no.)
Overall
homologyb Proposed function
orf9 140 SvirD4_010100037399 of S. viridochromogenes DSM
40736 (ZP_05536129)
87/93 Oxidoreductase
cpzDI 58 SAMR0798 of S. ambofaciens ATCC 23877 (CAJ88507) 64/75 Unknown
cpzDII 356 MtmD of S. argillaceus (CAK50774) 76/86 dTDP-glucose synthase
cpzDIII 327 NanG2 of S. nanchangensis (AAP42865) 77/83 dTDP-glucose dehydratase
cpzDIV 296 OleU of S. antibioticus (AAD55455) 63/71 4-Ketoreductase
cpzDV 268 SvirD4_010100037424 of S. viridochromogenes DSM
40736 (ZP_05536134)
96/99 Unknown
cpzDVI 202 StrM of S. glaucescens (CAA07389) 65/77 Sugar 3,5-epimerase
cpzDVII 647 SghaA1_010100002568 of S. ghanaensis ATCC 14672
(ZP_04684037)
76/82 Cell wall biosynthesis glycosyltransferase
orf10 170 SAMR0794 of S. ambofaciens ATCC 23877 (CAJ88503) 83/89 Phosphoesterase
a Genes shown in bold represent the proposed L-rhamnose subcluster.
b Homology is reported as percent identity/percent similarity.
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cpzEW08. Corresponding SpeI sites were added to the primer
sequence during the generation of cosmids cpzEW02 and
cpzEW05 (see Materials and Methods).
Three of the hypothetical genes in the L-rhamnose subclus-
ter have no obvious role in dTDP–L-rhamnose biosynthesis.
The potential glycosyltransferase CpzDVII contains several
conserved domains typical for glycan synthases and is most
likely involved in cell wall biogenesis. cpzDI is similar to small
hypothetical genes often located next to genes from deoxy-
sugar metabolism, and cpzDV encodes a putative protein with
unknown function. The genes cpzDI and cpzDV were individ-
ually deleted by replacement with an apramycin resistance
cassette flanked by loxP sites. Subsequently, the resistance
cassettes were eliminated in vitro using Cre recombinase. The
resulting cosmids were termed cpzEW10 (cpzDI) and
cpzEW12 (cpzDV). After introduction of the cosmids into S.
coelicolor M512, hygromycin- and kanamycin-resistant excon-
jugants were selected and designated S. coelicolor M512/
cpzEW10 and S. coelicolor M512/cpzEW12, respectively. After
cultivation, culture extracts of the mutants showed no differ-
ences in LC-ESI-MS analysis in comparison to S. coelicolor
M512/cpzEW07 containing the complete L-rhamnose cluster
(see Fig. S4 in the supplemental material). Caprazamycins
were accumulated by all of the strains. Therefore, we conclude
that cpzDI and cpzDV have no role in caprazamycin biosynthe-
sis and are probably involved in primary metabolism.
DISCUSSION
Based on the identification of the L-rhamnose biosynthetic
genes in this study, we propose two gene clusters, the capraza-
mycin and the L-rhamnose subcluster, to participate in
caprazamycin biosynthesis. Coexpression of pRHAM, contain-
ing all genes required for the biosynthesis of dTDP–L-rham-
nose, led to the accumulation of intact caprazamycins in a
heterologous producer strain harboring cosmid cpzLK09. This
clearly demonstrates that only the genes for the formation of
dTDP–L-rhamnose are missing in the heterologous capraza-
mycin producer. Thus, the genes directing the attachment and
methylation of the L-rhamnosyl moiety have to be carried on
cosmid cpzLK09. Three putative methyltransferases, Cpz28,
Cpz29, and Cpz30, show the highest sequence homology to
known rhamnose O-methyltransferases from elloramycin (47)
and spinosyn (54) biosynthesis. Most likely, these proteins have
similar functions in caprazamycin formation. Notably, the re-
cently identified gene cluster of liposidomycins, nonglyco-
sylated caprazamycin derivatives, did not contain any cpz28,
cpz29, or cpz30 orthologues (32).
Translationally coupled to the genes cpz28 to cpz30 is the
putative glycosyltransferase gene cpz31. An in vitro assay with
His8-Cpz31 using dTDP–L-rhamnose and caprazamycin agly-
cones as substrates showed a complete conversion of the agly-
cones after a 2-h incubation. The products were unambigu-
ously identified as 2c,3c,4c-desmethyl caprazamycins by LC-
ESI-MS/MS analysis. This result implies that attachment of the
deoxysugar occurs prior to its sequential methylation. A similar
order of sugar transfer and subsequent tailoring reactions has
been found in the biosynthesis of other glycosylated com-
pounds, such as tylosin (2), oleandomycin (50), mycinamycin
(26), and chromomycin (42). Cpz31, together with most glyco-
syltransferases involved in natural product biosynthesis, be-
longs to the GT-1 family of glycosyltransferases as classified by
the CAZy system (6). Cpz31 exhibits significantly higher ho-
mology to, for example, the 4,6-dideoxy-4-hydroxylamino--D-
glucosyltransferase CalG3 (36% identity, 50% similarity) from
Micromonospora echinospora (59) than to the rhamnosyltrans-
ferases AraGT (29% identiy, 38% similarity) from S. echinatus
(38) and SpnG (29% identity, 39% similarity) from Saccharo-
polyspora spinosa (5). Luzhetskyy et al. (39) proposed that
similarity-based relationships of glycosyltransferases are better
understood with consideration of the aglycone substrate than
of the sugar donor. In this aspect, Cpz31 is distinctive from
other known glycosyltransferases involved in natural product
biosynthesis. The rhamnosyl moiety of caprazamycins is linked
to the methylglutaryl moiety by an ester bond and not by a
glycosidic bond. While acylated deoxyhexoses are common in
plants, they are rare in bacterial secondary metabolism. So far,
only the phenazine derivatives aestivophoenins (35) and
phenazoviridins (30) and the rhamnopyranosides (21) have
been reported. Thus, Cpz31 may serve as a new enzymatic tool
for the modification of bioactive compounds in the future.
Rhamnosyltransferases have been frequently exploited
for the structural diversification of glycosylated antibiotics
(4, 15, 38, 44), as they often exhibit high flexibility towards
the donor substrate. However, heterologous expression of
cosmid cpzLK09 in S. fradiae A0, which produces the de-
oxysugars D-olivose and L-rhodinose, and Streptomyces sp.
TU¨6071plaA6, producing L-amicetose, did not lead to the
identification of new caprazamycin derivatives (data not
shown). Since the caprazamycin aglycones were readily de-
tected in the culture extracts, it can be speculated that
Cpz31 is more specific for dTDP–L-rhamnose than related
glycosyltransferases, e.g., ElmGT from S. olivaceus (4) or
StfG from S. steffisburgensis (44). Further investigations will
have to prove this assumption.
Screening of a cosmid library of the caprazamycin producer
Streptomyces sp. MK730F-62F2 led to the identification of
cpzDII, cpzDIII, cpzDIV, and cpzDVI elsewhere on the ge-
nome. The deduced gene products match the required en-
zymes for the biosynthesis of dTDP–L-rhamnose. Involvement
in caprazamycin biosynthesis was demonstrated by inactivation
of cpzDIII, resulting in the accumulation of caprazamycin
aglycones. In contrast, inactivation of the colocated genes
cpzDI and cpzDV had no influence on caprazamycin formation.
FIG. 5. (A) Strategy for assembly of the caprazamycin gene cluster and the L-rhamnose subcluster. aac(3)IV, apramycin resistance gene; aad4,
spectinomycin-streptomycin resistance gene; hyg, hygromycin resistance gene; loxP, Cre recognition site; oriT, origin of transfer. The size of the
resistance cassettes and their components are not drawn to scale. (B) LC-ESI-MS UV chromatogram and product ion chromatograms from mass
scans for caprazamycins E/F with m/z 1,118.6 [MH], caprazamycins C/D/G with m/z 1,132.6 [MH], and caprazamycins A/B with m/z 1,146.6
[MH] in butanolic extracts of S. coelicolor M512/cpzEW07.
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Based on the presented results, we propose the biosynthetic
pathway for the latter steps in caprazamycin biosynthesis as
follows (Fig. 6). Generation of the deoxysugar would start with
the activation of glucose-1-phosphate by the addition of de-
oxythymidyldiphosphate (dTDP), catalyzed by the putative
NDP-glucose synthase CpzDII. Subsequently, the glucose de-
hydratase CpzDIII would dehydrate dTDP-glucose to dTDP–
4-keto-6-deoxyglucose. This product would serve as a substrate
for the sugar 3,5-epimerase CpzDVI, resulting in dTDP–4-
keto-L-rhamnose, which would be further reduced to dTDP–
L-rhamnose by the 4-ketoreductase CpzDIV. Cpz31 would
than attach the L-rhamnose to the caprazamycin aglycones,
generating 2c,3c,4c,-demethyl caprazamycins. Sequential
methylation of the deoxysugar moiety by the putative O-meth-
yltransferases Cpz28, Cpz29, and Cpz30 would finally lead to
the caprazamycins.
Usually, genes involved in the formation of a bacterial sec-
ondary metabolite are clustered together. However, biosyn-
thetic gene clusters of rhamnosylated compounds often lack
the genes for L-rhamnose formation (9, 16, 38, 54). In the case
of elloramycin (48) and spinosyn (41), these genes were iden-
tified elsewhere in the genome. Inactivation experiments in
Saccharopolyspora spinosa suggested that the gtt, gdh, epi, and
kre genes provide the rhamnosyl moiety for both spinosyn and
cell wall biosynthesis. The presence of cpzDVII, a putative cell
wall biosynthesis glycosyltransferase gene, may indicate a sim-
ilar role for the L-rhamnose cluster in Streptomyces sp.
MK730F-62F2. However, L-rhamnose seems not to be essen-
tial for the strain, as inactivation of the glucose dehydratase
gene cpzDIII did result in a viable corresponding mutant.
In order to allow investigation of the entire biosynthetic
pathway of caprazamycins, we assembled the L-rhamnose and
caprazamycin gene cluster on cosmid cpzLK09, using a new
strategy based on Red/ET-mediated recombination. This tech-
nology, designated recombineering, was initially established
for DNA manipulations in E. coli (7, 60, 61) and has been
adapted to Streptomyces (18). It has been successfully applied
for functional studies and engineering of antibiotic biosyn-
thetic machineries (17), e.g., heterologous expression (10) and
combinatorial biosynthesis (11). More recently, recombineer-
ing was used for the reconstitution of large biosynthetic gene
clusters from overlapping inserts (3, 22, 57). This “stitching”
overcomes the problem that genomic library clones rarely con-
tain an entire gene cluster due to limitations of the average
insert sizes. While “stitching” relies on the presence of over-
lapping, identical DNA sequences in both clones, we now show
for the first time that assembly is possible without the need of
overlapping DNA regions. For the presented strategy, Red/
ET-mediated recombination is restricted to sequences in the
form of resistance cassettes. These cassettes were introduced
into the L-rhamnose donor cosmid and the recipient cosmid
harboring the caprazamycin gene cluster. Final assembly was
achieved by Red/ET-mediated recombination between a re-
striction fragment from the donor cosmid with the recipient
cosmid. FRT and loxP recognition sites and SpeI restriction
sites were introduced for the latter excision of the resistance
cassettes. The in vivo usage of Cre (13) and the Flp recombi-
nase (12) has now been successfully established in Streptomyces
and allows the rapid generation of unmarked deletions. How-
ever, if Cre or Flp recombinase is used, a “scar” sequence
comprising a loxP or an FRT site is maintained, which can
cause undesirable recombination events in further recom-
bineering experiments. Therefore, elimination of the apramy-
cin resistance cassette was performed with SpeI digestion and
religation of the cosmid DNA. In this study, cpzDI and cpzDV
were successfully deleted on the assembled cosmid and the
corresponding mutants were analyzed.
Since manipulation of natural producer strains can be diffi-
cult and time-consuming, heterologous expression of entire
biosynthetic gene clusters in more-amenable and fully se-
quenced host strains is desirable. In addition, formation of a
natural compound often relies on the supply of specific pre-
cursors provided by genes encoded outside the gene cluster,
e.g., deoxysugars (48), isoprenoid derived moieties (20), or
other small subunits (45, 58). Therefore, the new assembly
approach described in this study may help to establish heter-
ologous expression and genetic engineering of scattered gene
clusters.
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